Answers are grounded in this paper and cite their sources.
Acute graft-versus-host disease (aGVHD) is a leading cause of non-relapse mortality after allogeneic peripheral blood hematopoietic cell transplant (PB-HCT). The role of baricitinib, a balanced JAK1/2 inhibitor, for GvHD prophylaxis is unknown. Baricitinib after HLA-matched allogeneic PB-HCT was studied in a single-arm, open-label, phase I trial in 24 subjects. Subjects received baricitinib at 2 or 4 mg daily from days − 3 to + 100 post PB-HCT, followed by a taper. No primary graft failure, delayed engraftment or grade III/IV adverse events were observed. Overall incidence of grade III/IV aGVHD was 12.5% (3/24), of which 2/3 occurred after baricitinib discontinuation. Mild-moderate chronic GVHD occurred in 45.8% subjects, with no cases of severe chronic GVHD. Transplant-related mortality at day + 180 was 8% (2/24). The 1-year OS was 70% (95% CI 48–85%), PFS 62% (95% CI 40–78%), and refined GVHD and relapse free survival (GRFS) 33% (95% CI 15–52%). Correlative studies confirmed on-target effect of baricitinib resulting in downregulation of JAK1/2 pathways. Baricitinib is safe and tolerable after HLA-matched allogeneic PB-HCT with no episodes of primary graft failure and low rates of grade III/IV acute GVHD while on therapy.
No takes yet. Share an insight, caveat, or question.
Schroeder et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: